Literature DB >> 3770314

Apolipoprotein E polymorphism and hyperlipemia in type II diabetics.

M Eto, K Watanabe, Y Iwashima, A Morikawa, E Oshima, M Sekiguchi, K Ishii.   

Abstract

The relationship between apolipoprotein E (apoE) polymorphism and plasma lipids and hyperlipemia was investigated in 105 male type II diabetics and 111 male nondiabetics. ApoE phenotypes were determined by a one-dimensional rapid flat gel isoelectric focusing method as described previously. The apoE phenotype frequency in diabetics was similar to that in nondiabetics. The frequency of hyperlipemia was higher in diabetics (56.2%) than in nondiabetics (32.4%). It was highest in the apoE3/2 group of diabetics and nondiabetics, followed by the apoE4/3 and apoE3/3 groups in the order described, indicating that the susceptibility to hyperlipemia differs among the apoE phenotype groups. ApoE3/2 diabetics had significantly higher levels of apoE and very-low-density lipoprotein (VLDL) cholesterol (chol)/VLDL triglyceride (TG) ratios than apoE3/3 diabetics. The effects of diabetes mellitus on plasma lipid levels differed among the various apoE phenotype groups: i.e., plasma total chol and low-density lipoprotein (LDL) chol increased only in apoE3/2 and apoE4/3 diabetics and plasma high-density lipoprotein chol decreased only in apoE3/3 diabetics, as compared with the corresponding apoE phenotype groups of nondiabetics, whereas plasma TG, VLDL TG, and VLDL chol increased in the three apoE phenotype diabetics. Furthermore, an increase of apoEII:apoEIII ratio was observed in apoE3/3 diabetics, particularly in those with hypertriglyceridemia. This study has also shown that the increased apoEII:apoEIII ratio is due to increased sialation of apoE based on the study of sialidase digestion of apo VLDL.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3770314     DOI: 10.2337/diab.35.12.1374

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

Review 1.  Lipoprotein alterations in diabetes mellitus.

Authors:  G M Kostner; I Karádi
Journal:  Diabetologia       Date:  1988-10       Impact factor: 10.122

2.  Alterations in serum lipids and apolipoproteins in male type 1 (insulin-dependent) diabetic patients with microalbuminuria.

Authors:  R P Dullaart; L D Dikkeschei; H Doorenbos
Journal:  Diabetologia       Date:  1989-09       Impact factor: 10.122

3.  Apo E 2 phenotypes in type II diabetics with and without insulin therapy.

Authors:  K H Vogelberg; E Maucy
Journal:  Klin Wochenschr       Date:  1988-08-01

4.  Gender differences in a type 2 (non-insulin-dependent) diabetic population with respect to apolipoprotein E phenotype frequencies.

Authors:  M Boemi; R W James; F Romagnoli; P Gerber; D Pometta; P Fumelli
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

5.  Metabolism by human endothelial cells of very low density lipoprotein subfractions isolated from type 1 (insulin-dependent) diabetic patients.

Authors:  R L Klein; M F Lopes-Virella
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

6.  Rapid and safe determination of human apolipoprotein E genotypes by miniaturised SDS-PAGE in non-insulin dependent diabetes mellitus.

Authors:  C Clavel; A Durlach; V Durlach; P Birembaut
Journal:  J Clin Pathol       Date:  1995-04       Impact factor: 3.411

7.  Apolipoprotein E phenotypes and hyperlipidemia in patients under maintenance hemodialysis.

Authors:  G Feussner; S Wey; J Bommer; D Deppermann; P Grützmacher; R Ziegler
Journal:  Hum Genet       Date:  1992-01       Impact factor: 4.132

8.  Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon 4 allele.

Authors:  N Bergeron; R J Havel
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

9.  Relation of coronary heart disease and apolipoprotein E phenotype in patients with non-insulin dependent diabetes.

Authors:  M Laakso; A Kesäniemi; K Kervinen; M Jauhiainen; K Pyörälä
Journal:  BMJ       Date:  1991-11-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.